Rebecca C Harvey 1 , Gemma E Shields 1 , Anthony E James 2
• The network of evidence is presented in Figure 1 .
• Twelve interventions and placebo reported across ten studies are included in the analyses. Varying doses of the same intervention are classified uniquely in the analyses. • Relative treatment effects are presented as forest plots in Figure 2 .
• Whilst all treatments showed a reduction in total PANSS scores vs. • Haloperidol showed the greatest reduction in total PANSS scores (MD=-19.13). However, this result was not statistically significant.
• Nine out of thirteen treatments showed a trend of increased weight compared with placebo, but no pairwise comparisons were statistically significant.
• All treatments showed a trend of greater odds of discontinuation due to adverse events vs. placebo. However, no comparison was statistically significant.
• Treatment ranking probabilities showed that:
-Haloperidol (5-15mg/day) is likely to be the best treatment at reducing total PANSS scores (p=0.310).
-Olanzapine (2.5-20mg/day) is likely to be the worst treatment, causing weight gain (p=0.670).
• An SLR was conducted using two global electronic databases: MEDLINE and the Cochrane Central Register of Controlled Trials. This was performed to identify trials conducted in children and adolescents with schizophrenia that reported symptom control using the positive and negative syndrome scale (PANSS) -a medical scale frequently used for assessing the schizophrenia symptom severity. 3 • Bayesian NMAs were performed to synthesize data from the evidence base identified through the SLR, allowing comparisons to be made between treatments that have not been directly compared in head-to-head trials. 4 • The primary efficacy measure was mean change from baseline to 6 weeks in total PANSS scores.
• Secondary analyses included change in weight from baseline to 6 weeks and discontinuation due to adverse events.
• Analyses were performed using statistical software, WinBUGS and R, relying on Markov Chain Monte Carlo methods. 5, 6 • Random-effects models were fitted to the data; schizophrenia by its very nature was expected to occur in a heterogeneous population. The models used account for correlations between treatment effects arising from multi-arm trials, and were in line with the UK's National Institute for Health and Care Excellence (NICE) Decision Support Unit Technical Support Document 2. 7
• Non-informative prior distributions were assigned to the between-study heterogeneity, the relative treatment and study effects.
• Analyses were based on 10,000 samples after a burn-in of 50,000 samples was discarded. The Brooks-Gelman-Rubin plots were used to assess convergence. 8 A thinning interval was used to reduce autocorrelation between samples.
• Results are presented as forest plots with the point estimate and 95% credible intervals (CrI).
• Few studies discuss the effectiveness and side effects of the use of antipsychotics in the pediatric population, despite the poor prognosis associated with the disorder; this includes a high risk of suicide. Early diagnosis and effective treatment are imperative for pediatric schizophrenia due to the impact of the disorder on patients, which reduces their ability to live a productive and independent life.
• A previous study by Leucht et al. compared the efficacy and tolerability of antipsychotic drugs in the adult schizophrenia population using a network meta-analysis (NMA). 1 However, conclusions reached in the adult population cannot be applied to the pediatric population due to heterogeneity between the age groups.
• A systematic literature review (SLR) and NMA were carried out to explore the efficacy of trialled antipsychotics for early-onset schizophrenia (EOS) in children and adolescents, to determine which treatments are potentially efficacious in this population.
• In addition, the study considered discontinuation due to adverse events and weight gain (a common side effect of antipsychotics that may have a substantial impact on quality of life in the younger population due to both mental and physical effects). 2 • This study provides a comparison of the efficacy and side-effect profiles of different treatments for EOS.
• The analysis demonstrates that many of the treatments are efficacious in controlling symptoms (as shown by Figure 2A) . However, side effects resulting from treatment should be considered. Weight gain is commonly observed, and treatment discontinuation due to adverse events is variable between studies.
• The analysis for total PANSS scores showed that the most effective intervention was haloperidol in PANSS scores vs. placebo. Haloperidol is a first generation antipsychotic. This therefore raises some interesting questions associated with the use of second generation antipsychotics, particularly in light of the serious weight and cardio-metabolic side effects. These side effects have been described as an emerging health crisis. 9 • Study results differed from those of the NMA conducted by Leucht et al. on trials in the adult population, which highlights the lack of generalizability between the populations. 1
• Only trials reporting change in PANSS scores were included in the evidence base; a limitation of this being that not all interventions used to treat EOS in adolescents are evaluated in this NMA.
• The usefulness of existing trials completed in the pediatric population are often restricted by their quality, small sample numbers and heterogeneity amongst the study populations. 10 Due to the lack of data in this population, the literature search was not restricted to randomized controlled trials. This widened the evidence base, but increased the risk of bias in the NMA. Key: AEs, adverse events; CrI, credible interval; MD, median difference; mg, milligrams; OR, odds ratio; PANSS, positive and negative syndrome scale. Notes: In the trial evaluating haloperidol, all three arms contained zero events for discontinuation due to adverse events. Hence, this trial was not included in the analysis for this outcome ( Figure 2C ).
The SLR identified 1,613 potentially relevant citations through database searches (English language only with no date restriction)
Primary title and abstract screening (by two reviewers) resulted in 1,174 citations being excluded on the basis that they clearly did not meet the eligibility criteria of the review
Of the resulting 439 citations accessed in full, 11 were studies meeting the inclusion criteria Data extraction was performed by two reviewers to gather evidence for quantitative analysis
